Detalles de la búsqueda
1.
MDSC subtypes and CD39 expression on CD8+ T cells predict the efficacy of anti-PD-1 immunotherapy in patients with advanced NSCLC.
Eur J Immunol
; 50(11): 1810-1819, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32510574
2.
Therapeutic efficacy of cancer vaccine adjuvanted with nanoemulsion loaded with TLR7/8 agonist in lung cancer model.
Nanomedicine
; 37: 102415, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34174421
3.
AZD9291 overcomes T790 M-mediated resistance through degradation of EGFR(L858R/T790M) in non-small cell lung cancer cells.
Invest New Drugs
; 34(4): 407-15, 2016 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-27044261
4.
Susceptibility of CD24(+) ovarian cancer cells to anti-cancer drugs and natural killer cells.
Biochem Biophys Res Commun
; 427(2): 373-8, 2012 Oct 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-22995296
5.
Bevacizumab Plus Atezolizumab After Progression on Atezolizumab Monotherapy in Pretreated Patients With NSCLC: An Open-Label, Two-Stage, Phase 2 Trial.
J Thorac Oncol
; 17(7): 900-908, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35427805
6.
PD-1 blockade-unresponsive human tumor-infiltrating CD8+ T cells are marked by loss of CD28 expression and rescued by IL-15.
Cell Mol Immunol
; 18(2): 385-397, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-32332901
7.
Immunological Characteristics of Hyperprogressive Disease in Patients with Non-small Cell Lung Cancer Treated with Anti-PD-1/PD-L1 Abs.
Immune Netw
; 20(6): e48, 2020 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-33425433
8.
Regulatory (FoxP3+) T cells and TGF-ß predict the response to anti-PD-1 immunotherapy in patients with non-small cell lung cancer.
Sci Rep
; 10(1): 18994, 2020 11 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33149213
9.
Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment.
Oncoimmunology
; 9(1): 1722023, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32076579
10.
The First-week Proliferative Response of Peripheral Blood PD-1+CD8+ T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors.
Clin Cancer Res
; 25(7): 2144-2154, 2019 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30647082
11.
Mutational status of TP53 defines the efficacy of Wee1 inhibitor AZD1775 in KRAS-mutant non-small cell lung cancer.
Oncotarget
; 8(40): 67526-67537, 2017 Sep 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-28978051
12.
The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma.
Oncotarget
; 7(12): 14803-13, 2016 Mar 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-26909611
13.
A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non-Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib.
Clin Cancer Res
; 22(9): 2139-45, 2016 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-26667485
14.
Correction: The First-week Proliferative Response of Peripheral Blood PD-1+CD8+ T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors.
Clin Cancer Res
; 26(24): 6610, 2020 Dec 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33323362
Resultados
1 -
14
de 14
1
Próxima >
>>